The pattern of p53 and p21(WAF1/CIP1) immunoreactivity in non-Hodgkin's lymphomas predicts p53 gene status

被引:13
|
作者
Mansukhani, MM [1 ]
Osborne, BM [1 ]
Zhong, JY [1 ]
Matsushima, AY [1 ]
机构
[1] COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,VC14 215,NEW YORK,NY 10032
关键词
non-Hodgkin's lymphoma; p53 tumor suppressor gene; p21/waf1/cip1/sdi1; immunohistochemistry; PCR-SSCP;
D O I
10.1097/00019606-199708000-00006
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
P53 and p21(WAF1/CIP1) (p21) immunostaining was performed on 92 non-Hodgkin's lymphomas (NHLs), and the staining pattern correlated with the presence or absence of p53 hot spot mutations as detected by PCR-SSCP of exons 5-8 and direct sequencing. Twenty-nine of 92 lymphomas overexpressed p53, and 17 overexpressed p21. Of the p53 overexpressing lymphomas, 14 also overexpressed p21, and none of these 14 harbored a detectable hot spot mutation. However, mutations were detected in 13 (87%) of 15 p53 overexpressing, p21 negative lymphomas. One of the 63 p53-negative lymphomas harbored a detectable hot spot mutation, and it was also negative for p21. These results demonstrate that among NHLs that overexpress p53 protein, those which also show p21 overexpression do not harbor p53 hot spot mutations, and furthermore, provide evidence that the transactivating function of p53 is retained. On the other hand, p53 overexpression in NHLs that lack p21 expression is usually indicative of p53 gene mutation.
引用
收藏
页码:222 / 228
页数:7
相关论文
共 50 条
  • [1] Relationship of Waf1/P21 and p53 immunoreactivity and mutation in non-Hodgkin's lymphomas (NHLS)
    Mansukhani, MM
    Matsushima, AY
    Osborne, BM
    [J]. LABORATORY INVESTIGATION, 1996, 74 (01) : 676 - 676
  • [2] p21(Waf1/Cip1) and p53 protein expression in breast cancer
    Wakasugi, E
    Kobayashi, T
    Tamaki, Y
    Ito, Y
    Miyashiro, I
    Komoike, Y
    Takeda, T
    Shin, E
    Takatsuka, Y
    Kikkawa, N
    Monden, T
    Monden, M
    [J]. AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1997, 107 (06) : 684 - 691
  • [3] THE EXPRESSION AND SIGNIFICANCE OF P53 AND P21(WAF1/CIP1) IN THYROID CARCINOMA
    霍雄伟
    马清涌
    高燕凤
    孙学军
    刘浩
    盛薇
    [J]. Journal of Pharmaceutical Analysis, 2005, (01) : 86 - 89
  • [4] p53/p21((waf1/cip1)) expression in human lung cancer
    Bennett, WP
    ElDeiry, WS
    Guinee, DG
    Caporaso, NE
    Welsh, JA
    Jones, RT
    Borkowski, A
    Travis, WD
    Colby, TV
    Trastek, V
    Pairolero, PC
    Tazelaar, HF
    Midthun, D
    Jett, JR
    Liotta, LA
    Vogelstein, B
    Harris, CC
    [J]. LABORATORY INVESTIGATION, 1996, 74 (01) : 895 - 895
  • [5] Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas
    Hui, AM
    Kanai, Y
    Sakamoto, M
    Tsuda, H
    Hirohashi, S
    [J]. HEPATOLOGY, 1997, 25 (03) : 575 - 579
  • [6] Bcl-2, p21 (WAF1/CIP1) and p53 in pancreatic carcinoma
    Bruecks, A
    Saxena, A
    [J]. FASEB JOURNAL, 1998, 12 (04): : A196 - A196
  • [7] The interaction of taxol and vinblastine with radiation induction of p53 and p21(WAF1/CIP1)
    Tishler, RB
    Lamppu, DM
    [J]. BRITISH JOURNAL OF CANCER, 1996, 74 : S82 - S85
  • [8] p21(WAF1/CIP1) and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: A p53+, MDM2-, p21- immunophenotype associated with missense p53 mutations
    Villuendas, R
    Pezzella, F
    Gatter, K
    Algara, P
    SanchezBeato, M
    Martinez, P
    Martinez, JC
    Munoz, K
    Garcia, P
    Sanchez, L
    Kocialkowsky, S
    Campo, E
    Orradre, JL
    Piris, MA
    [J]. JOURNAL OF PATHOLOGY, 1997, 181 (01): : 51 - 61
  • [9] Abnormal p53 and p21(WAF1/CIP1) expression in Tamoxifen associated endometrial carcinomas
    Palazzo, J
    Ramondetta, L
    Dunton, C
    Kovatich, A
    [J]. LABORATORY INVESTIGATION, 1997, 76 (01) : 619 - 619
  • [10] p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma
    Qin, LF
    Ng, IOL
    Fan, ST
    Ng, M
    [J]. INTERNATIONAL JOURNAL OF CANCER, 1998, 79 (04) : 424 - 428